BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration

Dystrophy, Retinal Clinical Trial

Official title:

Brolucizumab-dbll (BEOVU®) Intravitreal Injection in the Treatment of Dystrophy-related Macular Neovascular Degeneration

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04690062
• Other study ID #: Hamaky7
• Status: Recruiting
• Phase: Phase 4
• Start date: October 25, 2020
• Est. completion date: December 30, 2022

Study information

• Verified date: December 2020
• Source: Benha University
• Contact: Tarek R Elhamaky, MD
• Phone: +97126324200
• Email: thamaky[@]ibnnafees.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.

Description:

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done.

Procedure included intravitreal injection of Brolucizumab (BEOVU®, Genen-tech, South Francisco, CA)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 30, 2022
• Est. primary completion date: December 25, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Dystrophy-Related macular neovascularization degeneration

Exclusion Criteria:

• age related macular degeneration , other causes of macular neovascularization degeneration

Related Conditions & MeSH terms

• Dystrophy, Retinal
• Retinal Dystrophies

Intervention

Drug:
• Brolucizumab-Dbll
intravitreal injection of Brolucizumab (BEOVU)

Locations

Country	Name	City	State
United Arab Emirates	INMC	Abu Dhabi

Sponsors (1)

Lead Sponsor	Collaborator
Benha University

Country where clinical trial is conducted

United Arab Emirates, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best corrected visual acuity (BCVA)	Change in BCVA in LOG MARS(logarithm minimum angle of resolution)	12 months
Secondary	optical coherence tomography (OCT) foveal thickness	change in foveal thickness measured in micrometer	12 months